A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer

by | Oct 15, 2026 | Clinical Trials | 0 comments

​ Conditions: High Risk Biochemical Recurrence (BCR); Deutenzalutamide Soft Capsules

Interventions: Drug: Deutenzalutamide Soft Capsules + ADT; Drug: Placebo + ADT

Sponsors: Hinova Pharmaceuticals Inc.

Not yet recruiting Conditions: High Risk Biochemical Recurrence (BCR); Deutenzalutamide Soft Capsules
Interventions: Drug: Deutenzalutamide Soft Capsules + ADT; Drug: Placebo + ADT
Sponsors: Hinova Pharmaceuticals Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *